Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNRNP200 | O75643 | 4/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | BRD2 | P25440 | 1/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.43 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28908654 | 0.89 | BRD4 (0.43) | SNRNP200BRD4BRD2BRD3BRDT | |
| SCHEMBL23856760 | 0.86 | BRD4 (0.44) | SNRNP200BRD4BRD2BRD3BRDT | |
| SCHEMBL13734925 | 0.70 | ALDH1A1 (0.44) | SNRNP200BRD4BRD2BRD3BRDT | |
| SCHEMBL8882974 | 0.69 | KMT2A (0.46) | BRD4ALDH1A1GAA | |
| SCHEMBL1640352 | 0.68 | LMNA (0.55) | BRD4BRD2BRD3BRDTALDH1A1 | |
| SCHEMBL13734781 | 0.68 | HTR2C (0.51) | SNRNP200MAPK14MAP4K1ALDH1A1LMNA | |
| SCHEMBL10017252 | 0.67 | MAPK14 (0.51) | SNRNP200BRD4BRD2BRD3BRDT | |
| SCHEMBL1014144 | 0.67 | MMP8 (0.47) | ALDH1A1 | |
| SCHEMBL30863938 | 0.67 | MMP8 (0.47) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30701473 | 0.67 | HTR2C (0.50) | SNRNP200MAPK14MAP4K1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126855-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-06-01 | — | — | US | disclosed |
| EP-4126855-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021190727-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2021-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | LTB4R, C5, C3AR1 | SNRNP200 4493/4885BRD4 355/4885BRD2 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.